Abeona Therapeutics (ABEO) Total Debt (2010 - 2026)

Abeona Therapeutics' Total Debt history runs 14 years deep, the most recent figure standing at $18.1 million for Q1 2026.

• On a quarterly basis, Total Debt fell 6.22% year-over-year to $18.1 million in Q1 2026; TTM through Mar 2026 was $18.1 million, a 6.22% decrease from a year earlier, with the FY2025 full-year figure at $20.0 million, up 5.65% from the prior year.
• Total Debt slipped to $18.1 million in Q1 2026 per ABEO's latest filing, from $20.0 million in the prior quarter.
• Across five years, Total Debt topped out at $22.8 million in Q1 2024 and bottomed at $4.2 million in Q4 2022.
• The 5-year median for Total Debt is $18.5 million (2024), against an average of $15.0 million.
• Biggest YoY gain for Total Debt was 402.22% in 2022; the steepest drop was 74.73% in 2022.
• Year by year, Total Debt stood at $4.2 million in 2022, then rose by 10.02% to $4.6 million in 2023, then surged by 314.04% to $19.0 million in 2024, then gained by 5.65% to $20.0 million in 2025, then declined by 9.72% to $18.1 million in 2026.
• Per Business Quant, the three latest ABEO Total Debt figures stand at $18.1 million (Q1 2026), $20.0 million (Q4 2025), and $19.8 million (Q3 2025).